XENON® is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Location: Canada, British Columbia, Burnaby
Employees: 51-200
Phone: +1 604-484-3300
Total raised: $265M
Investors 6
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Spur Capit... | spurcapita... |
| 24.11.2025 | Foresite C... | foresiteca... |
| - | Avoro Capi... | avorocapit... |
| - | InterWest ... | interwest.... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2022 | - | $250M | - |
| 30.01.2022 | - | $15M | - |
Mentions in press and media 19
| Date | Title | Description |
| 28.05.2024 | Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting | VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major... |
| 12.03.2024 | Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days | VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event... |
| 12.03.2024 | Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days | - |
| 05.03.2024 | Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 | - |
| 22.06.2022 | Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering | BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares an... |
| 12.01.2022 | Xenon Pharmaceuticals : Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone - Form 8-K | Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone BURNABY, British Columbia, January 12, 2022 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone | Xenon Pharmaceuticals Inc. announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. F... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone | BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine ... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone | BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine ... |
| 08.10.2021 | Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares | BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,00... |
Show more